



MERZ PHARMA CANADA LTD.

June 1, 2010

It is my pleasure to announce that Effective May 27, 2010 the Nova Scotia Department of Health accepted the recommendation of the Canadian Expert Drug Advisory and has listed Xeomin (clostridium botulinum Type A) 100u/vial as an Exception Status Drug Benefit under the Nova Scotia Pharmacare Programs with the following criteria:

- For treatment of blepharospasm and cervical dystonia (spasmodic torticollis)

About Xeomin®

Xeomin® is a neurotoxin therapy, free from complexing proteins, that combines high specific biologic activity with low bacterial protein load. It has been approved for marketing in Europe since 2005 to treat various movement disorders, and more recently was approved in Canada for symptomatic management of blepharospasm, cervical dystonia and post-stroke spasticity of the upper limb

About Merz

Merz Pharma Canada Ltd, a wholly owned subsidiary of the Merz Pharma Group of Companies was established in 2009 to commercialize Xeomin and expand other Merz franchises in the Canadian marketplace.

Merz Pharmaceuticals GmbH (www.merz.com):

Merz Pharmaceuticals, a member of the Merz Pharma Group of companies, is an innovative and international healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Merz is a leader in the field of neurology. In addition to developing Xeomin®, the company has developed memantine (Axura®) -- the first drug with a unique mechanism of action that focuses on the glutamatergic system for the treatment of moderate to severe Alzheimer's disease. The company also focuses on the development of innovative therapies within the therapeutic areas of hepatology, metabolic disease and dermatology.

I am very pleased that all appropriate patients will benefit from Xeomin® treatment and be reimbursed.

Please contact me if you have any questions.

Sincerely,

Glenn Block
President & General Manager
Merz Pharma Canada Ltd.